Inga Bauer graduated in Chemistry at the University of Bonn (Germany) in 2006. The project of her master thesis, under the supervision of Prof. Michael Famulok, focused on the establishment of a suitable cell system to study the inhibition of cytohesins by the small molecule inhibitor SecinH3 in terms of insulin and EGF signal transduction.
In 2010, she received her PhD in Experimental and Clinical Oncology and Hematology at the University of Genoa (Italy) in the laboratory of Prof. Silvio Parodi, working on the characterization of a c-Myc inhibiting cell permeable scFv antibody.
Afterwards, Dr. Bauer joined the group of Dr. Alessio Nencioni at the Department of Internal Medicine, University of Genoa (Italy) as a Post-doctoral Fellow, where she studied the mechanism by which Sirtuin 6, a NAD+-depending deacetylase, is involved in conferring an inflammatory phenotype to cancer cells and validated potential SIRT6 inhibitors that have been designed by an in-silico approach using the crystal structure of the protein.
Dr. Bauer has a consolidated knowledge in chemistry, biochemistry, molecular biology and cell biology. In particular, she has a solid expertise in cell culture, transfection methods, cloning and expression of recombinant proteins and detection of gene expression by real-time PCR, ELISA and Western blotting.
Dr. Bauer joined the Italian Institute of Technology (IIT) in February 2013 as a Post Doc in the Department of Drug Discovery and Development, Structural Biophysics.